Forbes reports on drug rebates: the free market is alive and well when it comes to drug prices – if you’re an insurance company or a government program. But not if you’re a consumer.
Good news for institutional pharmacies. Federal regulators have reversed a controversial proposal that would have required facilities to hire consultant pharmacists to review residents’ medications.